![conference banner](/images/conference-banner.jpeg)
Abstract
Breast cancer is subdivided into three types: hormone (estrogen and progesterone) receptor (ER and PR) positive, Her2-neu positive and triple negative breast cancers. In general, surgical and radiation treatments are similar, but drug treatment for different subtypes of breast cancers is different. Endocrine therapy (ET) is specifically used for the treatment of ER and PR positive breast cancers. This review discusses every aspect of endocrine therapy: ovarian suppression agents, selective estrogen receptor modulators (SERMs) and downregulators, and aromatase inhibitors (AIs). The most famous agents for the treatment of HER2 positive breast cancers are trastuzumab and its derivative Kadcyla (ado-trastuzumabemtansine). Other agents for the treatment of this subtype of breast cancers are also discussed. For the treatment of triple-negative breast cancers (TNBC) and other breast cancers, the following agents are discussed: anthracyclines and related regimens, taxanes, combination therapy of platinum with taxanes, combination therapy to counter drug resistance, ixabepilone and other epothilones, angiogenesis inhibitors. The lack of known specific molecular targets has promoted abundant research in order to find possible “vulnerabilities” in TNBC. For the first time, we propose thetranslocator protein (TSPO) 18 kDa as a potential target for TNBC. Furthermore, currently Photodynamic Therapy (PDT) is way under-explored for the treatment of breast cancers. In this review, PDT for the treatment of breast cancers is discussed. We also discuss imaging-guided therapy for breast cancers. Finally, from a perspective point of view, we call on the development of more potent agents for differentiation therapy.
Keywords: Breast cancer, differentiation-promoting agents, Her2-neu positive, hormone receptor positive, molecular treatment, photodynamic therapy, TNBC, translocator protein.
Anti-Cancer Agents in Medicinal Chemistry
Title:Molecular Treatment of Different Breast Cancers
Volume: 15 Issue: 6
Author(s): Yanfang Wang, Shousong Cao and Yihui Chen
Affiliation:
Keywords: Breast cancer, differentiation-promoting agents, Her2-neu positive, hormone receptor positive, molecular treatment, photodynamic therapy, TNBC, translocator protein.
Abstract: Breast cancer is subdivided into three types: hormone (estrogen and progesterone) receptor (ER and PR) positive, Her2-neu positive and triple negative breast cancers. In general, surgical and radiation treatments are similar, but drug treatment for different subtypes of breast cancers is different. Endocrine therapy (ET) is specifically used for the treatment of ER and PR positive breast cancers. This review discusses every aspect of endocrine therapy: ovarian suppression agents, selective estrogen receptor modulators (SERMs) and downregulators, and aromatase inhibitors (AIs). The most famous agents for the treatment of HER2 positive breast cancers are trastuzumab and its derivative Kadcyla (ado-trastuzumabemtansine). Other agents for the treatment of this subtype of breast cancers are also discussed. For the treatment of triple-negative breast cancers (TNBC) and other breast cancers, the following agents are discussed: anthracyclines and related regimens, taxanes, combination therapy of platinum with taxanes, combination therapy to counter drug resistance, ixabepilone and other epothilones, angiogenesis inhibitors. The lack of known specific molecular targets has promoted abundant research in order to find possible “vulnerabilities” in TNBC. For the first time, we propose thetranslocator protein (TSPO) 18 kDa as a potential target for TNBC. Furthermore, currently Photodynamic Therapy (PDT) is way under-explored for the treatment of breast cancers. In this review, PDT for the treatment of breast cancers is discussed. We also discuss imaging-guided therapy for breast cancers. Finally, from a perspective point of view, we call on the development of more potent agents for differentiation therapy.
Export Options
About this article
Cite this article as:
Wang Yanfang, Cao Shousong and Chen Yihui, Molecular Treatment of Different Breast Cancers, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (6) . https://dx.doi.org/10.2174/1871520615666150129211901
DOI https://dx.doi.org/10.2174/1871520615666150129211901 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually worldwide. GLOBOCAN 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040. In the future, female breast cancer will be the most common cancer (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pro-inflammatory Cytokines in Animal and Human Gestation
Current Pharmaceutical Design Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes
Anti-Cancer Agents in Medicinal Chemistry Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development
Current Pharmaceutical Design Editorial (Metastases Prevention is the Cure)
Current Cancer Therapy Reviews Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Challenging Axillary Lymph Nodes on PET/CT in Cancer Patients throughout COVID-19 Vaccination Era
Current Pharmaceutical Design Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Artificial Intelligence and Computer-aided Diagnosis in Medicine
Current Medical Imaging Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
Current Radiopharmaceuticals Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor
Current Medicinal Chemistry Genomics Can Advance The Potential For Probiotic Cultures To Improve Liver And Overall Health
Current Pharmaceutical Design Furanodiene: A Novel, Potent, and Multitarget Cancer-fighting Terpenoid
Current Pharmaceutical Design Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued)